Pancreatic Cancer Research

ResearcherPennsylvania State Univ Hershey Med CtrActive in the last 2 years

Pankaj Kumar Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8903-0131; OpenAlex author ID A5067292361, A5128838103, A5134893238; NIH RePORTER profile ID 10679629. Sources: OpenAlex.

Their work

Papers
57 (first author 2, last author 26)
Trials
0
Grants
8
Labs led
2
Collaborators
164
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 3 papers · 2017: 5 papers · 2018: 4 papers, 1 grant · 2019: 5 papers · 2020: 5 papers · 2021: 5 papers, 2 grants · 2022: 7 papers, 1 grant · 2023: 2 papers · 2024: 4 papers · 2025: 3 papers · 2026: 3 papers, 4 grants

Papers 50 of 57

  1. A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2026.218411↗
  2. KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-1984↗
  3. Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4534↗
  4. Tumor-stromal metabolic crosstalk in pancreatic cancer. Last author DOI 10.1016/j.tcb.2025.04.007↗
  5. A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. Co-author DOI 10.1021/acsnano.5c10607↗
  6. Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-025-68099-0↗
  7. Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells. Last author DOI 10.1007/978-1-0716-3633-6_14↗
  8. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Last author DOI 10.1038/s41556-024-01372-4↗
  9. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Last author DOI 10.1038/s41556-024-01417-8↗
  10. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Last author DOI 10.1073/pnas.2315509121↗
  11. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215981↗
  12. Erratum: Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. Co-author DOI 10.1016/j.isci.2023.108380↗
  13. Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. Co-author DOI 10.1016/j.isci.2022.104483↗
  14. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Last author DOI 10.1038/s41388-021-02132-6↗
  15. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02399-3↗
  16. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Co-author DOI 10.1038/s41598-022-05660-7↗
  17. The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1093/nar/gkac172↗
  18. Targeting keratin 17-mediated reprogramming of de novo pyrimidine biosynthesis to overcome chemoresistance in pancreatic cancer Co-author DOI 10.1101/2022.08.24.504873↗
  19. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-3230↗
  20. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Last author DOI 10.1053/j.gastro.2021.06.045↗
  21. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2562↗
  22. Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach. First author DOI 10.1158/1078-0432.ccr-21-0640↗
  23. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  24. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  25. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Co-author DOI 10.1016/j.bbcan.2020.188387↗
  26. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2020.04.017↗
  27. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. Last author DOI 10.1016/j.canlet.2020.07.025↗
  28. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  29. Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-19-2926↗
  30. Evaluating the Metabolic Alterations in Pancreatic Cancer. Last author DOI 10.1007/978-1-4939-8879-2_20↗
  31. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. Last author DOI 10.1007/978-1-4939-8879-2_28↗
  32. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  33. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cancers11091327↗
  34. Metabolic Alterations in Pancreatic Cancer Progression. Last author DOI 10.3390/cancers12010002↗
  35. Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia. Last author DOI 10.1007/978-1-4939-7665-2_23↗
  36. Evaluating the Metabolic Impact of Hypoxia on Pancreatic Cancer Cells. Last author DOI 10.1007/978-1-4939-7665-2_8↗
  37. Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. Last author DOI 10.1007/978-1-4939-7665-2_9↗
  38. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Last author DOI 10.3389/fphys.2018.00335↗
  39. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2017.04.029↗
  40. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2017.06.004↗
  41. Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.jproteome.7b00246↗
  42. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-16-3062↗
  43. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-17-1151↗
  44. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Co-author DOI 10.1021/acs.biomac.5b01419↗
  45. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Co-author DOI 10.1111/bph.13616↗
  46. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0156910↗
  47. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Last author DOI 10.18632/oncotarget.4078↗
  48. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Last author DOI 10.18632/oncotarget.5843↗
  49. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Co-author DOI 10.18632/oncotarget.5935↗
  50. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Co-author DOI 10.1021/bi401329a↗

Grants 8

  1. Targeting Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer R01CA163649↗
  2. Mitochondrial calcium signaling in pancreatic cancer metastasis and progression R01CA256911↗
  3. Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer R01CA270234↗
  4. MUC1 in Therapy Resistance U54CA274329↗
  5. Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
  6. Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer R01CA210439↗
  7. Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer R01CA216853↗
  8. Tissue Core P50CA127297↗

Closest collaborators

The 25 strongest of 164 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Anthony Hollingsworth · 14 shared papers, 3 shared grants, 2011–2026 · strength 2.90
  2. Surendra Kumar Shukla · 25 shared papers, 2014–2026 · strength 2.48
  3. Kamiya Mehla · 18 shared papers, 2012–2026 · strength 2.13
  4. Paul M. Grandgenett · 9 shared papers, 1 shared grant, 2011–2026 · strength 1.91
  5. Nina V. Chaika · 21 shared papers, 2012–2026 · strength 1.86
  6. Ravi Kumar Thakur · 9 shared papers, 2021–2026 · strength 1.70
  7. Aneesha Dasgupta · 14 shared papers, 2015–2024 · strength 1.38
  8. Shengyu Yang · 1 shared grant, 2026 · strength 1.26
  9. Kuldeep Singh Attri · 10 shared papers, 2017–2024 · strength 1.21
  10. Divya Murthy · 10 shared papers, 2017–2024 · strength 1.14
  11. Ryan J. King · 12 shared papers, 2015–2024 · strength 1.11
  12. Venugopal Gunda · 14 shared papers, 2014–2022 · strength 1.01
  13. Scott E. Mulder · 8 shared papers, 2017–2024 · strength 0.97
  14. Chunbo He · 6 shared papers, 2021–2026 · strength 0.87
  15. Jixin Dong · 1 shared grant, 2026 · strength 0.86
  16. Surinder K. Batra · 4 shared papers, 2 shared grants, 2012–2022 · strength 0.82
  17. Enza Vernucci · 10 shared papers, 2015–2022 · strength 0.78
  18. Jaime Abrego · 10 shared papers, 2015–2022 · strength 0.77
  19. Tuo Hu · 5 shared papers, 2021–2026 · strength 0.72
  20. Nicholas James Mullen · 3 shared papers, 2021–2025 · strength 0.62
  21. Vira Chumak · 2 shared papers, 2024–2026 · strength 0.58
  22. Sai Sundeep Kollala · 4 shared papers, 2021–2024 · strength 0.55
  23. Thomas C. Caffrey · 5 shared papers, 2011–2026 · strength 0.53
  24. Robert Powers · 7 shared papers, 2012–2024 · strength 0.50
  25. Susanna Varkey Ulahannan · 3 shared papers, 2024–2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.